Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments

被引：0
|
作者：
G. Grani
D. Tumino
V. Ramundo
L. Ciotti
C. Lomonaco
M. Armillotta
R. Falcone
P. Lucia
M. Maranghi
S. Filetti
C. Durante
机构：
[1] Sapienza University of Rome,Department of Translational and Precision Medicine
[2] University of Catania,Endocrinology, Department of Clinical and Experimental Medicine, Garibaldi
来源：
Journal of Endocrinological Investigation | 2019年 / 42卷
关键词：
Thyroid cancer; TSH variability; Levothyroxine dose adjustment; Real life; Hypothyroidism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1485 / 1490
页数：5
相关论文
共 50 条
  • [31] Absorbed dose coefficients for pediatric differentiated thyroid cancer patients undergoing radioiodine therapy
    Kwon, Tae-Eun
    Kitahara, Cari M.
    Lee, Choonsik
    JOURNAL OF RADIOLOGICAL PROTECTION, 2024, 44 (01)
  • [32] Blood dose calculation in radioiodine therapy of differentiated thyroid cancer
    Lassmann, M.
    Haenscheid, H.
    Chiesa, C.
    Luster, M.
    Bombardieri, E.
    Reiners, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S199 - S199
  • [33] Body composition changes in patients with differentiated thyroid cancer after iodine-131 treatment and short-term levothyroxine replacement and suppression therapy
    Wang, Ru
    Qin, Shanshan
    Qiao, Tingting
    Jiang, Wen
    Tong, Junyu
    Lu, Ganghua
    Gao, Dingwei
    Zhang, Mengyu
    Lv, Zhongwei
    Li, Dan
    Chai, Li
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2024, 23 (02): : 257 - 265
  • [34] Recombinant human thyrotropin (TSH) in the management of patients with differentiated thyroid cancer.
    McDougall, IR
    Weigel, RJ
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 323P - 323P
  • [35] Bone mineral density and serum markers of bone remodelling in patients treated with frantic-dose levothyroxine for differentiated thyroid cancer
    Mouton, F.
    D'Herbomez, M.
    Do Cao, C.
    Tison-Muchery, F.
    Marchandise, X.
    Wemeau, J. L.
    DIABETES & METABOLISM, 2007, 33 : S138 - S138
  • [36] SERUM THYROGLOBULIN LEVELS IN PATIENTS WITH WELL-DIFFERENTIATED THYROID-CANCER DURING SUPPRESSION THERAPY - STUDY ON 429 PATIENTS
    GIRELLI, ME
    BUSNARDO, B
    AMERIO, R
    SCOTTON, G
    CASARA, D
    BETTERLE, C
    PICCOLO, M
    PELIZZO, MR
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1985, 10 (5-6): : 252 - 254
  • [37] Altered bioavailability due to changes in the formulation of a commercial preparation of levothyroxine in patients with differentiated thyroid carcinoma
    Olveira, G
    Almaraz, MC
    Soriguer, F
    Garriga, MJ
    GonzalezRomero, S
    Tinahones, F
    deAdana, MSR
    CLINICAL ENDOCRINOLOGY, 1997, 46 (06) : 707 - 711
  • [38] The Levels of FT3/FT4 and Levothyroxine Dosage Required for TSH-Suppression in Differentiated Thyroid Carcinoma Patients Decrease over Time
    Verburg, F. A.
    Maeder, U.
    Luster, M.
    Reiners, C.
    Smit, J. W. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S375 - S375
  • [39] SUPPRESSION OF THE TSH RESPONSE TO TRH BY THYROXINE THERAPY IN DIFFERENTIATED THYROID-CARCINOMA PATIENTS
    LAMBERG, BA
    RANTANEN, M
    SAARINEN, P
    LIEWENDAHL, K
    SIVULA, A
    ACTA ENDOCRINOLOGICA, 1979, 91 (02): : 248 - 256
  • [40] Thyroglobulin levels after recombinant TSH in the follow-up of low-risk patients with differentiated thyroid cancer
    Vlassopoulou, V
    Vassilatou, E
    Botoula, E
    Gripeou, C
    Christoforaki, M
    Tzavara, I
    Thalassinos, N
    PROCEEDINGS OF THE 12TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY, 2004, : 1087 - 1090
12345